Cyndeo Wealth Partners LLC Buys 154 Shares of Danaher Co. (NYSE:DHR)

Cyndeo Wealth Partners LLC boosted its stake in shares of Danaher Co. (NYSE:DHR) by 1.8% in the 4th quarter, according to the company in its most recent disclosure with the SEC. The firm owned 8,579 shares of the conglomerate’s stock after buying an additional 154 shares during the quarter. Cyndeo Wealth Partners LLC’s holdings in Danaher were worth $1,969,000 as of its most recent SEC filing.

Other institutional investors have also added to or reduced their stakes in the company. Fort Pitt Capital Group LLC lifted its holdings in Danaher by 3.2% during the third quarter. Fort Pitt Capital Group LLC now owns 238,092 shares of the conglomerate’s stock valued at $66,194,000 after purchasing an additional 7,421 shares during the last quarter. Good Life Advisors LLC purchased a new stake in Danaher during the third quarter valued at about $217,000. ORG Partners LLC lifted its holdings in Danaher by 1,212.8% during the fourth quarter. ORG Partners LLC now owns 2,770 shares of the conglomerate’s stock valued at $636,000 after purchasing an additional 2,559 shares during the last quarter. Harvest Portfolios Group Inc. lifted its holdings in Danaher by 1.2% during the third quarter. Harvest Portfolios Group Inc. now owns 202,263 shares of the conglomerate’s stock valued at $56,233,000 after purchasing an additional 2,465 shares during the last quarter. Finally, Stifel Financial Corp lifted its holdings in Danaher by 1.3% during the third quarter. Stifel Financial Corp now owns 847,348 shares of the conglomerate’s stock valued at $235,583,000 after purchasing an additional 11,216 shares during the last quarter. 79.05% of the stock is owned by hedge funds and other institutional investors.

Danaher Stock Up 0.1 %

Shares of NYSE DHR opened at $245.95 on Friday. Danaher Co. has a one year low of $225.42 and a one year high of $281.70. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.37 and a quick ratio of 1.01. The firm’s 50 day simple moving average is $235.33 and its two-hundred day simple moving average is $253.45. The stock has a market capitalization of $177.65 billion, a P/E ratio of 46.94, a PEG ratio of 4.43 and a beta of 0.83.

Danaher Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, January 31st. Shareholders of record on Friday, December 27th will be given a dividend of $0.27 per share. This represents a $1.08 dividend on an annualized basis and a yield of 0.44%. The ex-dividend date is Friday, December 27th. Danaher’s payout ratio is currently 20.61%.

Analyst Ratings Changes

Several equities research analysts have commented on the stock. Royal Bank of Canada dropped their price objective on shares of Danaher from $333.00 to $311.00 and set an “outperform” rating on the stock in a report on Wednesday, October 23rd. Bank of America raised shares of Danaher from a “neutral” rating to a “buy” rating and set a $290.00 price target on the stock in a report on Friday, December 13th. TD Cowen increased their price target on shares of Danaher from $310.00 to $315.00 and gave the stock a “buy” rating in a report on Wednesday, October 23rd. Stephens reissued an “overweight” rating and issued a $315.00 price target on shares of Danaher in a report on Wednesday, October 23rd. Finally, Citigroup lowered their price target on shares of Danaher from $305.00 to $285.00 and set a “buy” rating on the stock in a report on Monday, January 6th. Six analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the company. According to MarketBeat.com, Danaher has an average rating of “Moderate Buy” and a consensus price target of $285.55.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.